Brokerages Set Sangamo Therapeutics Inc (SGMO) Price Target at $18.80
Sangamo Therapeutics Inc (NASDAQ:SGMO) has been given a consensus rating of “Hold” by the ten analysts that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $18.80.
SGMO has been the topic of several recent research reports. ValuEngine cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 10th. JPMorgan Chase & Co. cut Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $35.00 to $11.00 in a research report on Wednesday, November 14th. Guggenheim cut Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 price objective on the stock. in a research report on Friday, November 9th. BidaskClub cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 25th. Finally, Zacks Investment Research cut Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 18th.
SGMO stock traded up $0.49 during trading hours on Friday, hitting $8.81. 1,099,390 shares of the stock were exchanged, compared to its average volume of 2,471,546. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.32 and a quick ratio of 6.32. The stock has a market capitalization of $849.41 million, a price-to-earnings ratio of -12.59 and a beta of 2.84. Sangamo Therapeutics has a 12 month low of $6.26 and a 12 month high of $27.50.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SGMO. Wasatch Advisors Inc. grew its holdings in shares of Sangamo Therapeutics by 12.0% during the 3rd quarter. Wasatch Advisors Inc. now owns 4,544,596 shares of the biopharmaceutical company’s stock worth $77,031,000 after purchasing an additional 486,429 shares in the last quarter. Credit Suisse AG boosted its stake in Sangamo Therapeutics by 23.5% in the third quarter. Credit Suisse AG now owns 2,184,505 shares of the biopharmaceutical company’s stock valued at $37,027,000 after buying an additional 415,764 shares in the last quarter. Tocqueville Asset Management L.P. boosted its stake in Sangamo Therapeutics by 108.6% in the third quarter. Tocqueville Asset Management L.P. now owns 711,237 shares of the biopharmaceutical company’s stock valued at $12,055,000 after buying an additional 370,297 shares in the last quarter. Capital Fund Management S.A. acquired a new stake in Sangamo Therapeutics in the third quarter valued at about $4,637,000. Finally, BlackRock Inc. boosted its stake in Sangamo Therapeutics by 3.0% in the third quarter. BlackRock Inc. now owns 8,322,311 shares of the biopharmaceutical company’s stock valued at $141,063,000 after buying an additional 239,190 shares in the last quarter. 62.27% of the stock is currently owned by institutional investors.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Recommended Story: What factors cause inflation to rise?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.